ERCC1 and ovarian cancer: In addition, the ratios of larger ERCC1 to total ERCC1 mRNA following cisplatin treatment in ovarian cancer cells PEO14 and A2780 indicated increases from 41% to 98% and 54% to 79% respectively (Figure 4B).